{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T07:28:49Z","timestamp":1795159729318,"version":"4.10.3"},"reference-count":0,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2003,10,2]],"date-time":"2003-10-02T00:00:00Z","timestamp":1065052800000},"content-version":"vor","delay-in-days":2587,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[1996,9]]},"abstract":"<jats:p> <jats:bold>1<\/jats:bold>Statins inhibit synthesis of mevalonate, a precursor of ubiquinone that is a central compound of the mitochondrial respiratory chain. The main adverse effect of statins is a toxic myopathy possibly related to mitochondrial dysfunction.<\/jats:p><jats:p> <jats:bold>2<\/jats:bold>This study was designed to evaluate the effect of lipid\u2010lowering drugs on ubiquinone (coenzyme Q10) serum level and on mitochondrial function assessed by blood lactate\/pyruvate ratio.<\/jats:p><jats:p> <jats:bold>3<\/jats:bold>Eighty hypercholesterolaemic patients (40 treated by statins, 20 treated by fibrates, and 20 untreated patients, all 80 having total cholesterol levels &gt;6.0\u2003mmol l<jats:sup>\u22121<\/jats:sup>) and 20 healthy controls were included. Ubiquinone serum level and blood lactate\/pyruvate ratio used as a test for mitochondrial dysfunction were evaluated in all subjects.<\/jats:p><jats:p> <jats:bold>4<\/jats:bold>Lactate\/pyruvate ratios were significantly higher in patients treated by statins than in untreated hypercholesterolaemic patients or in healthy controls (<jats:italic>P<\/jats:italic>&lt;0.05 and <jats:italic>P<\/jats:italic>&lt;0.001). The difference was not significant between fibrate\u2010treated patients and untreated patients.<\/jats:p><jats:p> <jats:bold>5<\/jats:bold>Ubiquinone serum levels were lower in statin\u2010treated patients (0.75\u2003mg l<jats:sup>\u22121<\/jats:sup>\u00b10.04) than in untreated hypercholesterolaemic patients (0.95\u2003mg l<jats:sup>\u22121<\/jats:sup>\u00b10.09; <jats:italic>P<\/jats:italic>&lt;0.05).<\/jats:p><jats:p> <jats:bold>6<\/jats:bold>We conclude that statin therapy can be associated with high blood lactate\/pyruvate ratio suggestive of mitochondrial dysfunction. It is uncertain to what extent low serum levels of ubiquinone could explain the mitochondrial dysfunction.<\/jats:p>","DOI":"10.1046\/j.1365-2125.1996.04178.x","type":"journal-article","created":{"date-parts":[[2003,10,14]],"date-time":"2003-10-14T16:40:18Z","timestamp":1066149618000},"page":"333-337","source":"Crossref","is-referenced-by-count":199,"title":["Lipid\u2010lowering drugs and mitochondrial function: effects of HMG\u2010CoA reductase inhibitors on serum ubiquinone and blood lactate\/pyruvate ratio"],"prefix":"10.1111","volume":"42","author":[{"given":"G.","family":"DE PINIEUX","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"CHARIOT","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"AMMI\u2010SA\u00cfD","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"LOUARN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. L.","family":"LEJONC","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"ASTIER","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"JACOTOT","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"GHERARDI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2003,10,2]]},"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2125.1996.04178.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2125.1996.04178.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2125.1996.04178.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T21:57:18Z","timestamp":1698357438000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2125.1996.04178.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1996,9]]},"references-count":0,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1996,9]]}},"alternative-id":["10.1046\/j.1365-2125.1996.04178.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2125.1996.04178.x","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[1996,9]]}}}